Compare HOFT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | ENTX |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.4M | 147.4M |
| IPO Year | 1999 | 2015 |
| Metric | HOFT | ENTX |
|---|---|---|
| Price | $13.12 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 29.9K | ★ 324.6K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.10 | ★ 0.22 |
| Revenue | ★ $278,139,000.00 | $42,000.00 |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | $128.60 | ★ $13.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.62 | $0.91 |
| 52 Week High | $18.09 | $4.20 |
| Indicator | HOFT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 52.24 |
| Support Level | $11.99 | $2.66 |
| Resistance Level | $13.63 | $3.10 |
| Average True Range (ATR) | 0.53 | 0.23 |
| MACD | -0.16 | -0.07 |
| Stochastic Oscillator | 14.95 | 19.09 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.